The effect of peptide stimulation on haematopoietic stem cell mobilisation including engraftment characteristics and a note on donor side effects.
Aplasia or irreversible bone marrow failure and a variety of haematologic malignancies, as well as an increasing number of solid tumours, currently include various forms of marrow or equivalent transplantation in routine management. In both allogeneic and autologous procedures stable recipient immunohaematopoietic reconstitution depends upon infusing the requisite population harvested at a precise time following commencement of a stimulatory peptide. In a first step this prospective study documented the safety of apheresis, defined side effects and enumerated mononuclear, CD34+ and CD3+ cells obtained. In the second stage delivery of the graft, characterised in this way and with the additional measurement of in vitro growth in clonogenic assay, to the suitably conditioned patient was correlated with recovery of neutrophil and platelet numbers appearing in the circulation. In a third and ongoing analysis the influence of passenger T-lymphocytes is being evaluated for impact on infection and a potential anti-tumour effect. The conclusion is that this technology is reliable, has a high degree of patient acceptability without untoward complications, and that local results correspond to international experience thereby providing an important and relevant measure of quality control.
Barendse
Gameda
G
Department of Haematology and Bone Marrow Transplant Unit incorporating the Searll Laboratory for Research in Cellular and Molecular Biology, Constantiaberg Medi-Clinic, Burnham Road, Plumstead 7800, Cape Town, South Africa.
Tailford
Ruth
R
Wood
Lucille
L
Jacobs
Peter
P
D018952:Antigens, CD34 / Q000096:biosynthesis; D001781:Blood Component Removal / Q000379:methods; D017252:CD3 Complex / Q000096:biosynthesis; D005434:Flow Cytometry; D019337:Hematologic Neoplasms / Q000628:therapy; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods*; D006801:Humans; D007963:Leukocytes, Mononuclear / Q000378:metabolism; D010455:Peptides / Q000627:therapeutic use*; D011446:Prospective Studies; D013997:Time Factors; D014019:Tissue Donors; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous; D016896:Treatment Outcome
D018952:Antigens, CD34; D017252:CD3 Complex; D010455:Peptides